Supplementary Materials

Supplementary Material for:

A nontumorigenic variant of FGF19 treats cholestatic liver diseases

Jian Luo,* Brian Ko, Michael Elliott, Mei Zhou, Darrin A. Lindhout, Van Phung, Carmen To, R. Marc Learned, Hui Tian, Alex M. DePaoli, Lei Ling*

*Corresponding author. E-mail: lling@ngmbio.com (L.L.); jluo@ngmbio.com (J.L.)

Published 30 July 2014, Sci. Transl. Med. 6, 247ra100 (2014)
DOI: 10.1126/scitranslmed.3009098

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Liver is the major target tissue of transgene expression in the in vivo liver tumorigenesis system.
  • Fig. S2. Progression of liver tumor formation in db/db mice injected with AAVFGF19.
  • Fig. S3. Quantification of liver tumor area in db/db mice after 24 weeks of continuous exposure to FGF19 or M70.
  • Fig. S4. Study designs of BDL- and ANIT-induced mouse models of cholestasis.
  • Fig. S5. Effects of M70 on the expression of ileal bile acid transporters.
  • Table S1. Pharmacokinetic parameters of FGF19 and M70 recombinant proteins in C57BL6 mice.
  • Table S2. Quantification of hepatic lesions in BDL mice treated with FGF19 or M70.
  • Table S3. Quantification of hepatic lesions in ANIT mice treated with FGF19 or M70.
  • Table S4. Serum levels of 7α-hydroxy-4-cholesten-3-one (C4) in human subjects treated with M70 or placebo.
  • Table S5. Serum levels of total bile acids in human subjects treated with M70 or placebo.
  • Legend for table S6

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S6 (Microsoft Excel format). Summary of P values from statistical analysis for Figs. 3 to 5.

[Download Table S6]